Helicobacter has been identified in isolated cases of hepato-biliary diseases, however its role in the pathogenesis of these conditions remains unclear.
In this study, researchers determined whether Helicobacter could be detected in bile obtained at ERCP. They also evaluated the prevalence of this infection in patients with hepato-biliary diseases.
Their findings are published in the latest issue of Alimentary Pharmacology and Therapeutics.
The research team collected bile from 125 patients with various hepato-biliary diseases undergoing ERCP. Of these patients, 75 were diagnosed with biliary stones, 15 with pancreatico-biliary malignancies, and 4 with primary sclerosing cholangitis.
The team detected Helicobacter in DNA extracted from the bile samples using Helicobacter genus-specific primers.
The researchers detected Helicobacter in all positive controls.
|Helicobacter was detected in all positive controls.|
|Alimentary Pharmacology and Therapeutics|
They found that 3 samples had polymerase chain reaction inhibitors.
However, all remaining bile samples were found to be negative for Helicobacter DNA.
Dr Fallone’s team concluded, “Helicobacter can be detected in bile samples using polymerase chain reaction”.
“This infection, however, was not present in any of our patients diagnosed with gallstones or hepato-biliary malignancies, raising doubt as to the possible association between Helicobacter and these entities”.
However, “Given the low sample size of patients with primary sclerosing cholangitis, more studies are required to determine whether an association exists with this condition”.